CD19-specific chimeric antigen receptor (CAR)-modified T cells have antitumor activity in B cell malignancies, but factors that affect toxicity and efficacy have been difficult to define because of differences in lymphodepletion and heterogeneity of CAR-T cells administered to individual patients. We conducted a clinical trial in which CD19 CAR-T cells were manufactured from defined T cell subsets and administered in a 1:1 CD4+/CD8+ ratio of CAR-T cells to 32 adults with relapsed and/or refractory B cell non-Hodgkins lymphoma after cyclophosphamide (Cy)-based lymphodepletion chemotherapy with or without fludarabine (Flu). Patients who received Cy/Flu lymphodepletion had increased CAR-T cell expansion and persistence, and higher response rates [50% complete remission (CR), 72% overall response rate (ORR)] than patients who received Cy-based lymphodepletion without Flu (8% CR, 50% ORR). The CR rate in patients treated with Cy/Flu at the maximally tolerated dose was 64% (82% ORR; n = 11). Cy/Flu ...

BACKGROUND. Targeting CD30 with monoclonal antibodies in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) has had profound clinical success. However, adverse events, mainly mediated by the toxin component of the conjugated antibodies, cause treatment discontinuation in many patients. Targeting CD30 with T cells expressing a CD30-specific chimeric antigen receptor (CAR) may reduce the side effects and augment antitumor activity. METHODS. We conducted a phase I dose escalation study in which 9 patients with relapsed/refractory HL or ALCL were infused with autologous T cells that were gene-modified with a retroviral vector to express the CD30-specific CAR (CD30.CAR-Ts) encoding the CD28 costimulatory endodomain. Three dose levels, from 0.2 × 108 to 2 × 108 CD30.CAR-Ts/m2, were infused without a conditioning regimen. All other therapy for malignancy was discontinued at least 4 weeks before CD30.CAR-T infusion. Seven patients had previously experienced disease progression while being ...

BACKGROUND. Targeting CD30 with monoclonal antibodies in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) has had profound clinical success. However, adverse events, mainly mediated by the toxin component of the conjugated antibodies, cause treatment discontinuation in many patients. Targeting CD30 with T cells expressing a CD30-specific chimeric antigen receptor (CAR) may reduce the side effects and augment antitumor activity. METHODS. We conducted a phase I dose escalation study in which 9 patients with relapsed/refractory HL or ALCL were infused with autologous T cells that were gene-modified with a retroviral vector to express the CD30-specific CAR (CD30.CAR-Ts) encoding the CD28 costimulatory endodomain. Three dose levels, from 0.2 × 108 to 2 × 108 CD30.CAR-Ts/m2, were infused without a conditioning regimen. All other therapy for malignancy was discontinued at least 4 weeks before CD30.CAR-T infusion. Seven patients had previously experienced disease progression while being ...

BACKGROUND. Targeting CD30 with monoclonal antibodies in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) has had profound clinical success. However, adverse events, mainly mediated by the toxin component of the conjugated antibodies, cause treatment discontinuation in many patients. Targeting CD30 with T cells expressing a CD30-specific chimeric antigen receptor (CAR) may reduce the side effects and augment antitumor activity. METHODS. We conducted a phase I dose escalation study in which 9 patients with relapsed/refractory HL or ALCL were infused with autologous T cells that were gene-modified with a retroviral vector to express the CD30-specific CAR (CD30.CAR-Ts) encoding the CD28 costimulatory endodomain. Three dose levels, from 0.2 × 108 to 2 × 108 CD30.CAR-Ts/m2, were infused without a conditioning regimen. All other therapy for malignancy was discontinued at least 4 weeks before CD30.CAR-T infusion. Seven patients had previously experienced disease progression while being ...

BACKGROUND. Targeting CD30 with monoclonal antibodies in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) has had profound clinical success. However, adverse events, mainly mediated by the toxin component of the conjugated antibodies, cause treatment discontinuation in many patients. Targeting CD30 with T cells expressing a CD30-specific chimeric antigen receptor (CAR) may reduce the side effects and augment antitumor activity. METHODS. We conducted a phase I dose escalation study in which 9 patients with relapsed/refractory HL or ALCL were infused with autologous T cells that were gene-modified with a retroviral vector to express the CD30-specific CAR (CD30.CAR-Ts) encoding the CD28 costimulatory endodomain. Three dose levels, from 0.2 × 108 to 2 × 108 CD30.CAR-Ts/m2, were infused without a conditioning regimen. All other therapy for malignancy was discontinued at least 4 weeks before CD30.CAR-T infusion. Seven patients had previously experienced disease progression while being ...

BACKGROUND. Targeting CD30 with monoclonal antibodies in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) has had profound clinical success. However, adverse events, mainly mediated by the toxin component of the conjugated antibodies, cause treatment discontinuation in many patients. Targeting CD30 with T cells expressing a CD30-specific chimeric antigen receptor (CAR) may reduce the side effects and augment antitumor activity. METHODS. We conducted a phase I dose escalation study in which 9 patients with relapsed/refractory HL or ALCL were infused with autologous T cells that were gene-modified with a retroviral vector to express the CD30-specific CAR (CD30.CAR-Ts) encoding the CD28 costimulatory endodomain. Three dose levels, from 0.2 × 108 to 2 × 108 CD30.CAR-Ts/m2, were infused without a conditioning regimen. All other therapy for malignancy was discontinued at least 4 weeks before CD30.CAR-T infusion. Seven patients had previously experienced disease progression while being ...

BACKGROUND. Targeting CD30 with monoclonal antibodies in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) has had profound clinical success. However, adverse events, mainly mediated by the toxin component of the conjugated antibodies, cause treatment discontinuation in many patients. Targeting CD30 with T cells expressing a CD30-specific chimeric antigen receptor (CAR) may reduce the side effects and augment antitumor activity. METHODS. We conducted a phase I dose escalation study in which 9 patients with relapsed/refractory HL or ALCL were infused with autologous T cells that were gene-modified with a retroviral vector to express the CD30-specific CAR (CD30.CAR-Ts) encoding the CD28 costimulatory endodomain. Three dose levels, from 0.2 × 108 to 2 × 108 CD30.CAR-Ts/m2, were infused without a conditioning regimen. All other therapy for malignancy was discontinued at least 4 weeks before CD30.CAR-T infusion. Seven patients had previously experienced disease progression while being ...

BACKGROUND. Targeting CD30 with monoclonal antibodies in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) has had profound clinical success. However, adverse events, mainly mediated by the toxin component of the conjugated antibodies, cause treatment discontinuation in many patients. Targeting CD30 with T cells expressing a CD30-specific chimeric antigen receptor (CAR) may reduce the side effects and augment antitumor activity. METHODS. We conducted a phase I dose escalation study in which 9 patients with relapsed/refractory HL or ALCL were infused with autologous T cells that were gene-modified with a retroviral vector to express the CD30-specific CAR (CD30.CAR-Ts) encoding the CD28 costimulatory endodomain. Three dose levels, from 0.2 × 108 to 2 × 108 CD30.CAR-Ts/m2, were infused without a conditioning regimen. All other therapy for malignancy was discontinued at least 4 weeks before CD30.CAR-T infusion. Seven patients had previously experienced disease progression while being ...

BACKGROUND. Targeting CD30 with monoclonal antibodies in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) has had profound clinical success. However, adverse events, mainly mediated by the toxin component of the conjugated antibodies, cause treatment discontinuation in many patients. Targeting CD30 with T cells expressing a CD30-specific chimeric antigen receptor (CAR) may reduce the side effects and augment antitumor activity. METHODS. We conducted a phase I dose escalation study in which 9 patients with relapsed/refractory HL or ALCL were infused with autologous T cells that were gene-modified with a retroviral vector to express the CD30-specific CAR (CD30.CAR-Ts) encoding the CD28 costimulatory endodomain. Three dose levels, from 0.2 × 108 to 2 × 108 CD30.CAR-Ts/m2, were infused without a conditioning regimen. All other therapy for malignancy was discontinued at least 4 weeks before CD30.CAR-T infusion. Seven patients had previously experienced disease progression while being ...

BACKGROUND. Targeting CD30 with monoclonal antibodies in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) has had profound clinical success. However, adverse events, mainly mediated by the toxin component of the conjugated antibodies, cause treatment discontinuation in many patients. Targeting CD30 with T cells expressing a CD30-specific chimeric antigen receptor (CAR) may reduce the side effects and augment antitumor activity. METHODS. We conducted a phase I dose escalation study in which 9 patients with relapsed/refractory HL or ALCL were infused with autologous T cells that were gene-modified with a retroviral vector to express the CD30-specific CAR (CD30.CAR-Ts) encoding the CD28 costimulatory endodomain. Three dose levels, from 0.2 × 108 to 2 × 108 CD30.CAR-Ts/m2, were infused without a conditioning regimen. All other therapy for malignancy was discontinued at least 4 weeks before CD30.CAR-T infusion. Seven patients had previously experienced disease progression while being ...

BACKGROUND. Targeting CD30 with monoclonal antibodies in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) has had profound clinical success. However, adverse events, mainly mediated by the toxin component of the conjugated antibodies, cause treatment discontinuation in many patients. Targeting CD30 with T cells expressing a CD30-specific chimeric antigen receptor (CAR) may reduce the side effects and augment antitumor activity. METHODS. We conducted a phase I dose escalation study in which 9 patients with relapsed/refractory HL or ALCL were infused with autologous T cells that were gene-modified with a retroviral vector to express the CD30-specific CAR (CD30.CAR-Ts) encoding the CD28 costimulatory endodomain. Three dose levels, from 0.2 × 108 to 2 × 108 CD30.CAR-Ts/m2, were infused without a conditioning regimen. All other therapy for malignancy was discontinued at least 4 weeks before CD30.CAR-T infusion. Seven patients had previously experienced disease progression while being ...

BACKGROUND. Targeting CD30 with monoclonal antibodies in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) has had profound clinical success. However, adverse events, mainly mediated by the toxin component of the conjugated antibodies, cause treatment discontinuation in many patients. Targeting CD30 with T cells expressing a CD30-specific chimeric antigen receptor (CAR) may reduce the side effects and augment antitumor activity. METHODS. We conducted a phase I dose escalation study in which 9 patients with relapsed/refractory HL or ALCL were infused with autologous T cells that were gene-modified with a retroviral vector to express the CD30-specific CAR (CD30.CAR-Ts) encoding the CD28 costimulatory endodomain. Three dose levels, from 0.2 × 108 to 2 × 108 CD30.CAR-Ts/m2, were infused without a conditioning regimen. All other therapy for malignancy was discontinued at least 4 weeks before CD30.CAR-T infusion. Seven patients had previously experienced disease progression while being ...

BACKGROUND. Targeting CD30 with monoclonal antibodies in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) has had profound clinical success. However, adverse events, mainly mediated by the toxin component of the conjugated antibodies, cause treatment discontinuation in many patients. Targeting CD30 with T cells expressing a CD30-specific chimeric antigen receptor (CAR) may reduce the side effects and augment antitumor activity. METHODS. We conducted a phase I dose escalation study in which 9 patients with relapsed/refractory HL or ALCL were infused with autologous T cells that were gene-modified with a retroviral vector to express the CD30-specific CAR (CD30.CAR-Ts) encoding the CD28 costimulatory endodomain. Three dose levels, from 0.2 × 108 to 2 × 108 CD30.CAR-Ts/m2, were infused without a conditioning regimen. All other therapy for malignancy was discontinued at least 4 weeks before CD30.CAR-T infusion. Seven patients had previously experienced disease progression while being ...

BACKGROUND. Targeting CD30 with monoclonal antibodies in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) has had profound clinical success. However, adverse events, mainly mediated by the toxin component of the conjugated antibodies, cause treatment discontinuation in many patients. Targeting CD30 with T cells expressing a CD30-specific chimeric antigen receptor (CAR) may reduce the side effects and augment antitumor activity. METHODS. We conducted a phase I dose escalation study in which 9 patients with relapsed/refractory HL or ALCL were infused with autologous T cells that were gene-modified with a retroviral vector to express the CD30-specific CAR (CD30.CAR-Ts) encoding the CD28 costimulatory endodomain. Three dose levels, from 0.2 × 108 to 2 × 108 CD30.CAR-Ts/m2, were infused without a conditioning regimen. All other therapy for malignancy was discontinued at least 4 weeks before CD30.CAR-T infusion. Seven patients had previously experienced disease progression while being ...

Human immunodeficiency virus (HIV) is a causative agent of acquired immune deficiency syndrome (AIDS). Highly active antiretroviral therapy (HAART) can slow down the replication of HIV-1, leading to an improvement in the survival of HIV-1-infected patients. However, drug toxicities and poor drug administration has led to the emergence of a drug-resistant strain. HIV-1 immunotherapy has been continuously developed, but antibody therapy and HIV vaccines take time to improve its efficiency and have limitations. HIV-1-specific chimeric antigen receptor (CAR)-based immunotherapy founded on neutralizing antibodies is now being developed. In HIV-1 therapy, anti-HIV chimeric antigen receptors showed promising data in the suppression of HIV-1 replication; however, autologous transfusion is still a problem. This has led to the development of effective peptides and proteins for an alternative HIV-1 treatment. In this paper, we provide a comprehensive review of potent anti-HIV-1 peptides and proteins that reveal

The CD19 CAR Detection Reagent (Biotin) has been developed for the detection of transduced T cells that are engineered to express CD19-specific chimeric antigen receptors (CAR) on the cell surface, which recognize human CD19 antigen. The CD19 CAR Detection Reagent (Biotin) is an antigen based detection reagent conjugated to biotin. It contains a recombinantly expressed fusion protein consisting of the human CD19 extracellular domains and a specifically mutated human IgG1 Fc region. The engineered CD19 CAR T cells can be detected via the recognition of the CD19 protein, and identified by flow cytometry via anti-biotin fluorochromes. The mutated human IgG1 Fc region of the CD19 CAR Detection Reagent abolishes their binding to Fcγ receptors. This allows for background-free analysis and eliminates the need for additional blocking steps, such as using a FcR blocking reagent. - Ireland

Full Title A Phase I Trial Evaluating the Safety of Consolidative Infusions of CD19-Specific Chimeric Antigen Receptor (CAR) T Cells Following T-cell Depleted Allogeneic Transplantation for High Risk B-cell Malignancies Purpose CAR T-cell therapy is a type of immunotherapy. Normally during CAR T-cell therapy, a patients own T cells (a type of white blood cell) are removed and genetically modified in the laboratory to recognize a protein on their cancer cells.

Methods: T cells were activated with anti-CD3/28 antibodies and subsequently transduced with a bicistronic retrovirus encoding tandem Rim-binding domains (FKBP12v36),cloned in-frame with MyD88 and CD40 cytoplasmic signaling molecules, and first generation CAR targeting CD123 (SFG-iMC-CD123.ζ). The effects ofiMC costimulation on CD123-targeted CARs were assessed in coculture assays with CD123+, EGFPluciferase (EGFPluc)-modified leukemic cell lines (KG1, THP-1 and MOLM-13) with and without Rim using the IncuCyte live cell imaging system. IL-2 production was examined by ELISA from coculture supernatants. In vivo efficacy of iMC-CD123.ζ-modified T cells was assessed using an immune-deficient NSG tumor xenograft model. One million EGFPluc-expressing CD123+ THP-1 tumor cells were injected i.v. into the animals, followed by a single i.v. injection on day 7 with 2.5x106 non-transduced or iMC-CD123.ζ-modified T cells. Groups receiving CAR-T cells subsequently received i.p. injections of Rim (1 mg/kg) ...

Clinical study. We conducted a phase I study (NCT01316146) designed to assess the feasibility and safety of infusing escalating doses of autologous, polyclonally activated, peripheral blood T cells that were genetically modified to express a CD30-specific CAR (CD30.CAR) (31) encoding the CD28 endodomain in patients with relapsed/refractory CD30+ lymphoproliferative disorders (HL and non-Hodgkin lymphoma). All patients with a diagnosis of HL had CD30 positivity determined by a pathologist according to her/his institutional hematopathology standard measured against positive and negative controls. In all those cases, the Reed-Sternberg cells were deemed CD30+ and CD15+ (in a membrane/Golgi pattern, when described). Patient 2 (ALK- ALCL) had malignant cells that were also reported by a pathologist to be positive for CD30, CD4, and epithelial membrane antigen (EMA). Patient 9 (ALK+ ALCL), who had the best response, had malignant cells that were described as having strong membranous and cytoplasmic ...

Downloading a figure as powerpoint requires a browser with javascript support. Enable javascript and try again For help please contact [email protected] ...

As of 2015, a Dodge Hemi can be purchased at Dodge, Cars.com and AutoTrader. The label Hemi refers to the engine type and not a specific car model. Currently there are two Dodge vehicles with a Hemi,...

We provide custom professional service to remap ECU files for specific cars. We are doing this job since 2009 with a very big success rate of clients satisfaction. Look at our feedbacks and enjoy the new power. Life is too short to have a stock car:). Read More ...

How can I relabel a graph or pie chart in excel 2010 so that it has the name of the color of the data(color of specific car sold) instead of the numbers(1,2,3etc) It is a graph and pie chart that is associated with the formulas in the cells and the numbers associated with it ...

The nuclear matrix (also known as the nucleoplasm) contains many ribosomes and chromatin (chromosomes). The outer membrane of the nucleus contains many pores that allow molecules to move in and out of the nucleus. ...

Title:Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer. VOLUME: 13 ISSUE: 5. Author(s):Feng Li, Tengfei Zhang, Ling Cao and Yi Zhang*. Affiliation:Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan. Keywords:Cancer immunotherapy, CAR T cells, hematologic malignancies, solid tumor, cancer cells, leukemia.. Abstract:Cancer immunotherapy, a new weapon against cancers by harnessing the patients own immune system, potentiates an extended remission and possibly a cure for cancer. T cells genetically engineered with chimeric antigen receptor (CAR) vectors can specifically target the surface antigen of cancer cells and kill them in an MHC-independent manner. CD19 is extensively ...

Cancer therapy and diagnosis have long been challenges for humans. Despite accumulated knowledge and information, there are many complications and difficulties with cancer therapy and diagnosis. The challenges of cancer treatment are modified according to the new forms that have been discovered by researchers. Each stage of development has involved new techniques for cancer therapy, culminating in the modern immunotherapy approach using chimeric antigen receptor (CAR) cytotoxic T lymphocytes. This strategy is an example of the latest version of cancer cell therapy. Chimeric antigen receptor T-cell therapy drew interest soon after its implementation by researchers as a new strategy to control various types of cancer cells, and it is considered a living drug in the body that detects and destroys cancer cells in a long-term manner, with CAR T-cells remaining as memory cells. CAR T-cell therapy has shown remarkable effects against both primary acute lymphoblastic leukemia (ALL) and relapsed ALL, with a high

The success of adoptive T cell gene transfer for treatment of cancer and HIV is predicated on generating a response that is both durable and safe. We report long-term results from three clinical trials to evaluate gammaretroviral vector-engineered T cells for HIV. The vector encoded a chimeric antigen receptor (CAR) composed of CD4 linked to the CD3ζ signaling chain (CD4ζ). CAR T cells were detected in 98% of samples tested for at least 11 years after infusion at frequencies that exceeded average T cell levels after most vaccine approaches. The CD4ζ transgene retained expression and function. There was no evidence of vector-induced immortalization of cells; integration site distributions showed no evidence of persistent clonal expansion or enrichment for integration sites near genes implicated in growth control or transformation. The CD4ζ T cells had stable levels of engraftment, with decay half-lives that exceeded 16 years, in marked contrast to previous trials testing engineered T cells. ...

Background T cells engineered to express chimeric antigen receptors (CARs) have established efficacy in the treatment of B-cell malignancies, but their relevance in solid tumors remains undefined....

General structure of Chimeric Antigen Receptor T tagged: molecular pathology, cancer, tcr, cd28, til, cancer immunotherapy, immunotherapy, tumor infiltrating lymphocytes, scfv, itam, immune response, cd3, powerpoint, slide

CC Grand Rounds (1) Treating Hematologic Malignancies with Chimeric Antigen Receptor T Cells and (2) Human Papilloma Virus (HPV)-Targeted T Cell Therapy for Patients with HPV-Associated Cancers

Comments, concepts and statistics about Long-term persistence and function of hematopoietic stem cell-derived chimeric antigen receptor T cells in a nonhuman primate model of HIV/AIDS.

This is a Phase 1, multicenter, open-label study of CC-98633, BCMA-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in subjects with relapsed and/or refractory multiple myeloma. The study will consist of 2 parts: dose-escalation (Part A) and dose-expansion (Part B). The dose-escalation part (Part A) of the study is to evaluate the safety and tolerability of increasing dose levels of CC-98633 to establish a recommended Phase 2 dose (RP2D); and the dose-expansion part (Part B) of the study is to further evaluate the safety, pharmacokinetics/pharmacodynamics, and efficacy of CC-98633 at the RP2D.

Beijing Immunochina Medical Science and Technology is developing anti-CD19 IM19 chimeric antigen receptor (CAR) T cells for leukaemia. The CAR-T cells are

TY - JOUR. T1 - Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. AU - the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network. AU - Mahadeo, Kris M.. AU - Khazal, Sajad J.. AU - Abdel-Azim, Hisham. AU - Fitzgerald, Julie C.. AU - Taraseviciute, Agne. AU - Bollard, Catherine M.. AU - Tewari, Priti. AU - Duncan, Christine. AU - Traube, Chani. AU - McCall, David. AU - Steiner, Marie E.. AU - Cheifetz, Ira M.. AU - Lehmann, Leslie E.. AU - Mejia, Rodrigo. AU - Slopis, John M.. AU - Bajwa, Rajinder. AU - Kebriaei, Partow. AU - Martin, Paul L.. AU - Moffet, Jerelyn. AU - McArthur, Jennifer. AU - Petropoulos, Demetrios. AU - OHanlon Curry, Joan. AU - Featherston, Sarah. AU - Foglesong, Jessica. AU - Shoberu, Basirat. AU - Gulbis, Alison. AU - Mireles, Maria E.. AU - Hafemeister, Lisa. AU - Nguyen, Cathy. AU - Kapoor, Neena. AU - Rezvani, Katayoun. AU - Neelapu, Sattva S.. AU - Shpall, Elizabeth J.. PY - 2019/1/1. Y1 - 2019/1/1. N2 - In ...

There has been a lot of recent buzz about chimeric antigen receptor (CAR) T cell technology. Novartis and Gilead have FDA-approved CAR-T therapies...

The blood cells of cancer patients, reprogrammed by doctors to attack their leukemia and re-infused back into the patients veins, led to complete remissions in 27 of 30 people. Thats especially exciting because those patients had failed all conventional treatments. Not all of the remissions lasted. Nineteen patients in the study remain in remission 2 to 24 months later, and 15 of them didnt need any additional treatment. Seven patients relapsed between 6 months and 9 months after their infusion; those included three people whose cancers spread beyond the blood cells the new treatment targets. Five patients left the study for alternative therapy. The numbers are remarkable because these patients had cancer return as many as four times before they joined the study, including some whose cancer had returned after stem cell transplants. For this method, the researchers harvest a patients T cells using a process like blood transfusion. Then the lab [performs] a gene transfer, to teach the T cells ...

This patent search tool allows you not only to search the PCT database of about 2 million International Applications but also the worldwide patent collections. This search facility features: flexible search syntax; automatic word stemming and relevance ranking; as well as graphical results.

This patent search tool allows you not only to search the PCT database of about 2 million International Applications but also the worldwide patent collections. This search facility features: flexible search syntax; automatic word stemming and relevance ranking; as well as graphical results.

Chimeric antigen receptor (CAR) therapy targeting CD19 is an effective treatment for refractory B cell malignancies, especially acute lymphoblastic leukemia (ALL) |sup|1|/sup| . Although a majority of patients will achieve a complete response following a single infusion of CD19-targeted CAR-modified …

Chimeric Antigen Receptor (CAR) T cells have great efficacy against CD19 + leukemia but little success to solid tumors. This study explored the effectiveness of anti-HER2 cells CAR-T third generation ...

Survey FL6 is appropriate for laboratories that perform flow cytometric analysis on samples from patients treated with chimeric antigen receptor (CAR) T-cell or other immunotherapy regimens that cause immunophenotypic changes to normal and/or neoplastic cells. ...

The era of powerful, personalized medicine draws near. The treatment-known as chimeric antigen receptor (CAR) T cell therapy-belongs to a relatively new class of cancer treatments called immunotherapy, which empowers a patients immune system to eliminate cancer.

Chimeric antigen receptor (CAR)-T cell therapy harnesses the power of the patients own immune system to combat cancer. In theory, CAR-T cell therapy is simple; extract the patients own T-cells, modify them with a viral vector to express an artificial chimeric receptor specific for a cancer antigen, and re-infuse the cells back into the patient. […]. [Read More] ...

Is immunotherapy with chimeric antigen receptor (CAR)-directed T cells the next big thing in oncology? Presentations and discussion at a recent conference suggest the technology has considerable pro

Although administration of anti-CD19 chimeric antigen receptor (CAR)-T cell therapy takes place at authorized treatment centers, community...

This clinical trial is an open-label, single-centre, dose escalation, phase I study designed to investigate the safety and tolerability of Haploidentical...

Clinical trial for Lymphocytic Leukemia | Acute | Non-Hodgkins Lymphoma | B-Cell | Leukemia | B-Cell Lymphoma | Chronic | Chronic Lymphocytic Leukemia | childhood ALL | Lymphoma , CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

PRIMARY OBJECTIVES:. I. Determine the feasibility of producing CD19/CD22-CAR T cells meeting the established release criteria.. II. Assess the safety of administering escalating doses of autologous CD19/CD22-CAR T cells that meet established release specifications in adults with hematologic malignancies following a cyclophosphamide/fludarabine phosphate (fludarabine) conditioning regimen.. SECONDARY OBJECTIVES:. I. Evaluate the ability of CD19/CD22-CAR T cells to mediate clinical activity in adults with B cell malignancies.. TERTIARY OBJECTIVES:. I. Evaluate the frequency of CD22+ expression on lymphoma cells, and determine site density when possible.. II. Analyze alterations in early B cell development induced by immune pressure exerted via CD19/CD22-CAR T cells.. III. Evaluate whether subjects receiving CD19/CD22-CAR T cells relapse with loss or diminished expression of CD19 and/or CD22, when feasible.. IV. Measure persistence of CD19/CD22-CAR T cells in the blood, bone marrow and ...

TY - JOUR. T1 - Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy. AU - Hung, Chien Fu. AU - Xu, Xuequn. AU - Li, Linhong. AU - Ma, Ying. AU - Jin, Qiu. AU - Viley, Angelia. AU - Allen, Cornell. AU - Natarajan, Pachai. AU - Shivakumar, Rama. AU - Peshwa, Madhusudan V.. AU - Emens, Leisha A.. N1 - Funding Information: We thank Dario Campana for providing the OP-1 cells. We also thank Jeremy Foote and Andrew Wang for assistance with the figures. Writing assistance was supported by MaxCyte, Inc., and provided by Biologics Consulting. Financial support for these studies was provided by MaxCyte, Inc., and NCI P30 CA006973. This work was presented as a poster at the 2017 annual meeting of the American Association for Cancer Research. Funding Information: These studies were funded by MaxCyte, Inc. C.F.H. and L.A.E. received financial and material support from MaxCyte, Inc. L.L., A.V., C.A., P.N., ...

Correction: In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia.

p { margin-bottom: 0.25cm; line-height: 120%; }a:link { } DelveInsights, Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape,...

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy Christine E. Brown, Ph.D., Darya Alizadeh, Ph.D., Renate Starr, M.S., Lihong Weng, M.D., Jamie R. Wagner, B.A., Araceli Naranjo, B.A., Julie R. Ostberg, Ph.D., M. Suzette Blanchard, Ph.D., Julie Kilpatrick, M.S.N., Jennifer Simpson, B.A., Anita Kurien, M.B.S., Saul J. Priceman, Ph.D., Xiuli Wang, M.D., Ph.D., Todd…

On August 30th, 2017, the FDA approved the first CAR T-Cell Therapy, Kymriah™, for children and young adults up to age 25 with B-cell Acute Lymphocytic Leukemia that is refractory or in second or greater relapse. There has been an urgent need for novel treatment options that improve outcomes for patients with relapsed or refractory (r/r) B-cell precursor ALL, whose prognosis is poor. Patients often undergo multiple treatments including chemotherapy, radiation, targeted therapy or stem cell transplant, yet less than 10% of patients survive five years.. The FDA approval of Kymriah™ is based on the results of the pivotal open-label, multicenter, single-arm Phase II ELIANA trial, the first pediatric global CAR-T cell therapy registration trial, examining patients in 25 centers in the US, EU, Canada, Australia and Japan. In this study, 68 patients were infused and 63 were evaluable for efficacy. Results show 83% of patients who received treatment with Kymriah™ achieved complete remission or ...

Many EBV-associated cancers express virally-encoded transmembrane proteins. Two such proteins Latent Membrane Protein1 (LMP1) and Latent Membrane Protein 2 (LMP2) that play roles in oncogenesis. Both are multi-spanning transmembrane proteins, with a small extracellular region that is exposed on the surface of the infected cell. Our hypothesis is that the exposed extracellular regions of LMP1 and LMP2 could be targeted by cytotoxic T cells expressing chimeric antigen receptors (CARs). However, the development of CAR based therapies to target LMP-expressing malignancies are currently hampered by a lack of antibodies that recognize the extracellular domains of these proteins. Using a humanized mouse model, we are working to isolate human antibodies that specifically recognize the extracellular domains of membrane-anchored LMP1 and LMP2, and to convert these antibodies into chimeric antigen receptors that can be used to direct potent T-cell-mediated killing to EBV+ cancer cells.. ...

CAR T-cell therapy is one of a group of new treatments, called immunotherapy, that harnesses the power of the bodys immune system to detect and destroy cancer cells.

Dr. Marco Ruella and his collaborators at the University of Pennsylvania are working to develop combination strategies that will improve outcomes for cancer…

CAR T細胞免疫療法也並非是完美的療法，須注意的是「細胞因子風暴(免疫風暴)」，其為此療法在臨床應上最主要的不良反應。此風暴產生的原因是當CAR-T細胞在殺死癌細胞時，會釋放許多蛋白(即:細胞因子)，其作用是啟動更多的...

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. ...

News Analysis Love in the Scientific Literature There are countless ways for scientists to say, I love you. Naming a slime-mold beetle after your wife (and another after your ex-wife) is, apparently, one of them. ...

2012 GMC Canyon Extended Cab SLE Pickup 4D 6 ft can come with different options. Select the car equipment for your 2012 GMC Canyon Extended Cab SLE Pickup 4D 6 ft and let Kelley Blue Book provide you with a specific car value.

First up, lets cover fuel octane rating. What is an octane rating? Well, fueleconomy.gov states, Octane rating is the measure of a fuels ability to resist knocking or pinging during combustion, caused by the air/fuel mixture detonating prematurely in the engine. In the U.S., unleaded gasoline typically has octane ratings of 87 (regular), 88-90 (midgrade), and 91-94 (premium). Most cars run off of regular (87) octane fuel. Its affordable and does the job perfectly, but a lot of high end, luxury and sports cars require higher octane ratings. (Consult your owners manual for the exact octane rating your specific car is designed to use.) The reason for this is they use higher compression engines that make more horsepower. The trade-off is that these engines require a higher octane fuel in order to not knock. If you have one of these cars that require a midgrade or premium fuel and you are running a regular fuel instead, it can definitely cause a knocking concern.. ...

2007 BMW 7 Series 760Li Sedan 4D can come with different options. Select the car equipment for your 2007 BMW 7 Series 760Li Sedan 4D and let Kelley Blue Book provide you with a specific car value.

Carmakers release new models every year with advanced technology to attract consumer interest and to satisfy increasingly stringent government regulations. Some of these technologies are firsts or leading-edge, and they start trends that more companies will soon follow. Snapshots of the direction of the automotive industry, along with OEM and supplier perspectives, are presented in these articles that have been collected by the Editors of Automotive Engineering whose aim is to provide the reader with a complete overview of the key advances that took place over the course of one model year. • Provides a single source for information on the key engineering trends of one year. • Allows the reader to skip to chapters that cover specific car models that interest them, or read about all models from beginning to end. • Includes plenty of big, full-color images and the facts about the most recent technology and engineering innovations ...

STOCKHOLM, SWEDEN - A novel chimeric antigen receptor T-cell construct directed against CD22 was able to rescue children with relapsed or refractory B-cell acut

In high-risk patients with chronic lymphocytic leukemia (CLL), CD19 chimeric antigen receptor (CAR) T-cells of defined composition can be administered with an acceptable early toxicity.

The research team recruited 15 patients for this trial who had either relapsed or never responded to CD19-targeted CAR-T therapy, which involves extracting a population of T cells from patients and adapting them with a chimeric antigen receptor so they would target a protein commonly found on the surface of leukemia cells. Ten of them had relapsed, with their cancer cells no longer expressing CD19.. After stepping up the dose from the first round, the researchers achieved remission in 11 of the 15 patients - a remarkable 73%. The remissions lasted a median of 6 months with one patient in remission at 21 months, with signs that the cancer cells were able to mutate to stop expressing CD22 and escape the therapeutic assault.. The take-home message is that weve found another CAR T-cell therapy that displays high-level activity in this Phase I trial, said Stanfords Crystal Mackall, who led the study. But the relapse rate was also high. So this forces the field to get even more sophisticated. How ...

In high-risk patients with chronic lymphocytic leukemia (CLL), CD19 chimeric antigen receptor (CAR)-T cells of defined composition can be administered with an acceptable early toxicity.

Chinese doctors have reported success with a new type of immunotherapy for multiple myeloma*, a blood cancer: 33 out of 35 patients in a clinical trial had clinical remission within two months. The researchers used a type of T cell called chimeric antigen receptor (CAR) T.** In a phase I clinical trial in China, the patients own T cells were collected, genetically reprogrammed in a lab, and injected back into the patient. The reprogramming involved inserting an artificially designed gene… read more. ...

Chinese doctors have reported success with a new type of immunotherapy for multiple myeloma*, a blood cancer: 33 out of 35 patients in a clinical trial had clinical remission within two months. The researchers used a type of T cell called chimeric antigen receptor (CAR) T.** In a phase I clinical trial in China, the patients own T cells were collected, genetically reprogrammed in a lab, and injected back into the patient. The reprogramming involved inserting an artificially designed gene… read more. ...

A clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer.

A new cancer treatment being studied at a few major centers including UW Health is CAR T (Chimeric Antigen Receptor T cell) therapy. CAR T therapy uses a patients own cells and reengineers them to ...

While buysiders do not expect any sector-moving milestones in the wake of a catalyst-heavy third quarter, they will have at least 21 Phase III milestones and 23 PDUFA dates on their radar. But the biggest milestones on their minds are commercial milestones: the launches of chimeric antigen receptor T cell (CAR T) therapies Kymriah tisagenlecleucel from Novartis AG and Gilead Sciences Inc.s newly acquired axicabtagene ciloleucel.

Genetic Engineering and Biotechnology News - February 8th, 2021 - Products from Novartis and Gilead proved it was possible to win regulatory approval for chimeric antigen receptor T cell (CAR-T) based therapies in 2017. Since then both drugs have illustrated the challenges involved in commercializing such products.. ...